Sweden's Calliditas seeks $75M IPO haul to bring its oral steroid to patients with an orphan kidney disease
As biotech after biotech elicits enthusiastic investor support for this corner of the IPO market, a Swedish player is joining the Nasdaq line to fund …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.